BALICH-WONDER-STUDIO
29.12.2021 14:05:13 CET | Business Wire | Press release
A new magical experience has just lit up in the middle of the desert. People could live a unique emotion by attending the Candlelight Concert , an atmospheric musical performance set in the archaeological site of Hegra (AlUla, Saudi Arabia) , the UNESCO World Heritage Site famous for having more than 100 monumental tombs carved from rock formations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005155/en/
The archaeological site, just 22 minutes far from the city of AlUla, has never been used for concerts of such intimate character.
The first concert that took place on the 24th December 2021 and the next one that will take place on the 31st December 2021 are produced by Balich Wonder Studio , the live entertainment group, leader in the creation and production of large-scale ceremonies, events and shows, brand and territorial experiences worldwide.
The audience live a full emotional experience by listening to the evocative repertoire performed live by the Stefan Lombard ensemble (piano, violin, cello and oud ). The famous South African musical Director has created a suite (a collection of short musical pieces) from classic compositions to contemporary, Arab, movie soundtracks and a revised take on pop music .
More than 500 high-tech candles are the magic surrounding of these musical performances: sculpted by hand, they allow spectacular graphic patterns that emotionally enhance the special moments by blending harmoniously with the forms of the archaeological site, creating a landmark that merges the suggestions of the past and the dynamic of the contemporary .
The events exploit the latest technologies as the candles thanks to their various control possibilities, can shine all night, cozily shaping the surrounding and could reach four times the brightness of a traditional candle without burning or melting: the unique color combination allows for the same warmth as a real flame candle . In addition, its innovative algorithm can make an entire set of candles flicker differently, just like real candles would.
These two special events are exclusive occasions within the suggestive AlUla Moments Season, specifically designed for ‘Winter At Tantora’. The whole season is filled with high-end cultural, musical, wellness and arts events, as well as star-studded concerts, adventurous activities and immersive heritage experiences . BWS-KSA, the branch of the Balich Wonder Studio group based in Saudi Arabia, has been appointed by the Royal Commission for AlUla to produce multiple activities throughout the entire season that will enfold in late March.
The area and the city of AlJadidah has become an exclusive gathering spot, divided in various hubs where different cultures from all over the world, itinerant performing artists and the best of the circus arts will mix and mingle in the spirit of nomadic culture and the traditional Saudi Arabian hospitality with the aim to attract the widest audience and be inclusive.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005155/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom